Revolution's pan-RAS drug clears path to Phase III in pancreatic cancer

In a presentation to investors Monday, Revolution Medicines said its RAS(ON) multi-selective inhibitor RMC-6236 will advance to Phase III testing in pancreatic cancer following encouraging results from a Phase I study. The biotech shared updated results showing tumour shrinkage of up to 27% in patients with pancreatic ductal adenocarcinoma (PDAC).